Cargando…
Role of C-Reactive Protein in Predicting the Severity and Response of Immune-Mediated Diarrhea and Colitis in Patients with Cancer
Background: Immune-mediated diarrhea and colitis (IMDC) frequently develop after treatment with immune checkpoint inhibitors. C-reactive protein (CRP) is a serum inflammatory biomarker used to stratify and monitor disease severity in many inflammatory conditions. However, CRP level is not specific a...
Autores principales: | Liu, Cynthia, Shatila, Malek, Mathew, Antony, Machado, Antonio Pizuorno, Thomas, Austin, Zhang, Hao Chi, Thomas, Anusha S., Faleck, David, Funchain, Pauline, Philpott, Jessica, Grivas, Petros, Obeid, Michel, Carbonnel, Franck, Wang, Yinghong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10355204/ https://www.ncbi.nlm.nih.gov/pubmed/37476185 http://dx.doi.org/10.7150/jca.84261 |
Ejemplares similares
-
Obesity Measured via Body Mass Index May Be Associated with Increased Incidence but Not Worse Outcomes of Immune-Mediated Diarrhea and Colitis
por: Kono, Miho, et al.
Publicado: (2023) -
Colon Adenoma After Diagnosis of Immune Checkpoint Inhibitor-mediated Colitis
por: Machado, Antonio Pizuorno, et al.
Publicado: (2023) -
The Safety of Immunosuppressants Used in the Treatment of Immune-Related Adverse Events due to Immune Checkpoint Inhibitors: a Systematic Review
por: Machado, Antonio Pizuorno, et al.
Publicado: (2023) -
Incidence of immune checkpoint inhibitor–mediated diarrhea and colitis (imDC) in patients with cancer and preexisting inflammatory bowel disease: a propensity score–matched retrospective study
por: Sleiman, Joseph, et al.
Publicado: (2021) -
Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study
por: Zou, Fangwen, et al.
Publicado: (2021)